T6422

Brimonidine Tartrate (AGN190342 tartrate) is a quinoxaline derivative and adrenergic α-2 receptor agonist (EC50: 0.45 nM) that is used to manage intraocular pressure associated with open-angle glaucoma or ocular hypertension.

Linvencorvir is a hepatitis B virus (HBV) core protein variant modifier used to treat chronic HBV infection.

Cyclophilin inhibitor 3 (compound 7c), a potent inhibitor of cyclophilin A (CypA), exhibited potent anti-HCV effects with an EC50 value of 4.2 μM.

Antitumor agent-55 (compound 5q) is a potent antitumor compound that inhibits PC3 with an IC50 of 0.91 μM. It blocks the G1/S phase of the PC3 cell cycle, induces apoptosis, inhibits cell migration, and prevents PC3 formation.

RMS5 is a hambanine analogue and a potent P-glycoprotein (P-gp) inhibitor.RMS5 has significant anti-proliferative and cytotoxic effects on cancer cells.RMS5 slightly reduces the expression of the anti-apoptotic Bcl-2 family proteins Bcl-XL and Mcl-1.RMS3 causes cleavage of PARP, a marker of apoptosis.RMS5 has strong anti-cancer properties. RMS5 has strong anti-cancer properties.

Sacibertinib is a tyrosine kinase (Trk) inhibitor with activity against EGFR-TK phosphorylation (EC50: 110 nM) and HER2 (EC50: 244 nM), demonstrating antitumor effects.

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent, selective FLT3 inhibitor with an IC50 of 0.22 μM and also effectively inhibits c-Kit and PDGFR, with IC50 values of 0.17 μM and 0.20 μM, respectively. This compound is clinically applicable for treating acute myelogenous leukemia (AML) and can cross the blood-brain barrier.

JAK2 JH2 binder-1 is a potent and selective JAK2 JH2 binder (Ki: 37.1 nM). JAK2 JH2 binder-1 has the potential to be used in the study of various myeloproliferative neoplasms.

ALDH1A1-IN-3 is a good and selective inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1) (IC50: μM).ALDH1A1-IN-3 is effective in improving glucose consumption in HepG2 cells.ALDH1A1-IN-3 can be used for studies to improve glucose metabolism.

SENP2-IN-1 is a selective inhibitor of SENP2. SENP2-IN-1 inhibits SENP1 (IC50: 1.3 μM), SENP2 (IC50: 0.69 μM) and SENP5 (IC50: 22.7 μM). SENP2-IN-1 can be used in cancer research.